EMERGENT Competitors

ER4 Stock

EUR 9.49 0.01 0.11%

EMERGENT BIOSOLUT competes with Dave Busters, Playa Hotels, TFS FINANCIAL, Hanover Insurance, and Tencent Music; as well as few others. Analyzing EMERGENT BIOSOLUT competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of EMERGENT BIOSOLUT to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out EMERGENT BIOSOLUT Correlation with its peers.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of EMERGENT BIOSOLUT competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
2.65	9.49	16.33

Details

Intrinsic

Valuation

Low	Real	High
0.62	7.46	14.30

Details

Naive

Forecast

Low	Next	High
2.69	9.54	16.38

Details

Bollinger

Band Projection (param)

Lower	Middle Band	Upper
7.66	8.95	10.24

Details

EMERGENT BIOSOLUT Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between EMERGENT BIOSOLUT and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of EMERGENT and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of EMERGENT BIOSOLUT does not affect the price movement of the other competitor.

	9DB	PL0	PWT	AF4	7E3	63TA	BOZA	YT2A
9DB		0.84	0.67	0.73	0.36	0.36	-0.36	-0.59	9DB
PL0	0.84		0.91	0.94	0.68	0.32	-0.41	-0.49	PL0
PWT	0.67	0.91		0.93	0.86	0.05	-0.36	-0.42	PWT
AF4	0.73	0.94	0.93		0.82	0.29	-0.38	-0.38	AF4
7E3	0.36	0.68	0.86	0.82		0.01	-0.36	-0.17	7E3
63TA	0.36	0.32	0.05	0.29	0.01		-0.24	0.1	63TA
BOZA	-0.36	-0.41	-0.36	-0.38	-0.36	-0.24		0.37	BOZA
YT2A	-0.59	-0.49	-0.42	-0.38	-0.17	0.1	0.37		YT2A
	9DB	PL0	PWT	AF4	7E3	63TA	BOZA	YT2A

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

AF4	+ 0.94	PL0
AF4	+ 0.93	PWT
PWT	+ 0.91	PL0
7E3	+ 0.86	PWT
PL0	+ 0.84	9DB
7E3	+ 0.82	AF4

High negative correlations

YT2A	- 0.59	9DB
YT2A	- 0.49	PL0
YT2A	- 0.42	PWT
BOZA	- 0.41	PL0
YT2A	- 0.38	AF4
BOZA	- 0.38	AF4

Risk-Adjusted Indicators

There is a big difference between EMERGENT Stock performing well and EMERGENT BIOSOLUT Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze EMERGENT BIOSOLUT's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
9DB	2.90	0.13	0.09	0.19	2.94	(3.61)	7.69	(4.73)	18.54
PL0	1.56	0.25	0.17	0.31	1.26	(2.15)	3.65	(2.16)	15.83
PWT	1.30	(0.03)	0.03	0.11	1.24	(1.92)	3.01	(2.50)	12.15
AF4	1.17	0.26	0.15	0.64	0.84	(1.68)	2.92	(1.94)	7.20
7E3	2.34	0.27	0.10	0.33	2.62	(2.86)	6.99	(4.19)	13.90
63TA	2.27	0.33	0.04	(0.35)	2.31	(2.93)	5.56	(4.50)	21.17
BOZA	2.95	0.04	(0.02)	(0.09)	3.38	(4.90)	4.17	(4.00)	20.74
YT2A	0.71	(0.06)	0.00	(0.10)	0.00	0.00	1.33	(2.38)	4.66

Unable to evaluate fundamental data of [9DB.F, PL0.F, PWT.BE, AF4.F, 7E3.F, 63TA.F, BOZA.F, YT2A.BE] at this time. Please try again later

All Fundamental Data

EMERGENT BIOSOLUT Competitive Analysis

The better you understand EMERGENT BIOSOLUT competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, EMERGENT BIOSOLUT's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across EMERGENT BIOSOLUT's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	ER4	9DB	PL0	PWT	AF4	7E3	63TA	BOZA	YT2A
	0.11 9.49 EMERGENT	0.56 35.40 Dave	1.10 9.20 Playa	0.75 13.30 TFS	2.60 158.00 Hanover	1.76 1.73 PLAYSTUDIOS	1.92 10.60 Tencent	4.00 0.01 BOZA	1.54 4.49 ATRESMEDIA
Market Volatility (90 Days Market Risk)	Relatively risky	Not too volatile	Not too volatile	Not too volatile	Very steady	Very risky	Somewhat reliable	Out of control	Not too volatile
Market Performance (90 Days Performance)	Modest	OK	Good	OK	Solid	OK	Modest	Very Weak	Very Weak
Odds of Financial Distress (Probability Of Bankruptcy)	About Average	Low	Low	Low	Low	Unknown	Low	Low	Low
Current Valuation (Equity Enterprise Value)	Over Valued	Over Valued	Under Valued	Fairly Valued	Under Valued	Over Valued	Over Valued	Over Valued	Fairly Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Strong Sell	Strong Sell	Strong Sell	Strong Sell	Strong Sell	Strong Sell	Strong Sell	Strong Sell	Strong Sell
Current Ratio	N/A	0.28	2.01	N/A	0.37		N/A	N/A	N/A
Net Asset	3.17 B	2.35 B	2.07 B	15.79 B	14 B		67.25 B	168.76 T	1.41 B
Profit Margin	N/A	0.0709	0.067	N/A	0.0212		N/A	0.21	N/A
EBITDA	(41.1 M)	315.65 M	193.69 M	N/A	191 M		4.75 B	N/A	183.37 M
Current Valuation	1.34 B	4.26 B	1.61 B	N/A	5.28 B		10.7 B	1.43 B	843.76 M
Price To Book	0.43	4.74	1.31	2.09	2.19		1.96	0.6	1.13
Operating Margin	N/A	0.15	0.14	N/A	0.0326		N/A	N/A	N/A
Five Year Return	N/A	N/A	N/A	N/A	2.0		N/A	N/A	N/A
Beta	N/A	1.94	1.55	N/A	0.69		N/A	0.99	N/A
Number Of Employees	18	13.78 K	14.1 K	N/A	4.6 K		N/A	9.47 K	29
Shares Outstanding	N/A	48.29 M	158.23 M	N/A	35.6 M		N/A	388.15 M	N/A
Cash Flow From Operations	(34.1 M)	283.13 M	158.23 M	38.93 M	722.3 M		5.24 B	3.43 T	193.77 M
Annual Yield	N/A	0.0593	N/A	0.0653	0.0234		N/A	0.0321	0.2
Total Debt	448.5 M	431.39 M	1.06 B	4.79 B	782.4 M		5.06 B	2.09 B	260.36 M
Return On Equity	N/A	0.41	0.0875	N/A	0.0427		N/A	0.0597	N/A
Z Score	2.4	2.4	0.6	N/A	3.0		1.2	N/A	1.8
Return On Asset	N/A	0.0539	0.0368	N/A	0.0079		N/A	0.0106	N/A
Book Value Per Share	N/A	7.48	4.2	N/A	65.33		N/A	0.022	N/A
Total Asset	3.17 B	2.35 B	2.07 B	15.79 B	14 B		67.25 B	168.76 T	1.41 B
Debt To Equity	N/A	430.8	115.5	N/A	0.25		N/A	N/A	N/A
Target Price	N/A	50.0	9.67	N/A	152.33		N/A	N/A	N/A
Last Dividend Paid	N/A	N/A	N/A	0.25	3.06		N/A	N/A	0.2
Shares Owned By Institutions	N/A	97.35	82.0	N/A	88.13		N/A	0.02	N/A
Market Capitalization	1.91 B	1.93 B	1.31 B	4.5 B	4.68 B		10.16 B	1.12 B	807.37 M
Price To Earning	N/A	11.65	22.15	N/A	10.73		N/A	7.05	N/A
Price To Earnings To Growth	N/A	N/A	N/A	N/A	N/A		1.36	N/A	N/A
Price To Sales	0.42	0.95	1.15	13.13	0.88		3.13	1.82	0.85
Net Income	(223.8 M)	108.64 M	56.71 M	74.56 M	116 M		3.03 B	1.64 T	118.54 M
Earnings Per Share	N/A	2.38	0.45	N/A	3.04		N/A	N/A	N/A
Shares Owned By Insiders	N/A	2.65	22.3	N/A	0.83		N/A	81.33	N/A
Revenue	1.12 B	1.3 B	856.26 M	291.2 M	5.47 B		31.24 B	9.47 T	877.87 M
Cash And Equivalents	N/A	20.35 M	111.02 M	N/A	106.4 M		N/A	492.24 M	N/A
Cash Per Share	N/A	0.56	0.85	N/A	2.98		N/A	0.01	N/A
Gross Profit	N/A	409.16 M	392.77 M	N/A	752 M		N/A	7.44 T	N/A
Day Typical Price	9.49	35.4	9.13	13.3	156.33	1.73	10.67	0.013	4.49
Accumulation Distribution	N/A	N/A	0.0217	N/A	0.0316	0.0058	0.0721	N/A	N/A
Market Facilitation Index	N/A	N/A	0.2	N/A	5.0	0.01	0.8	N/A	N/A
Daily Balance Of Power	(9,223,372,036,855)	(9,223,372,036,855)	0.5	(9,223,372,036,855)	0.8	3.0	0.25	9.2 T	(9,223,372,036,855)
Period Momentum Indicator	(0.01)	(0.20)	0.1	(0.10)	4.0	0.03	0.2	5.0E-4	(0.07)
Rate Of Daily Change	1.0	0.99	1.01	0.99	1.03	1.02	1.02	1.04	0.98
Day Median Price	9.49	35.4	9.1	13.3	155.5	1.73	10.7	0.013	4.49
Price Action Indicator	(0.01)	(0.10)	0.15	(0.05)	4.5	0.02	N/A	3.0E-4	(0.04)
Relative Strength Index	68.06	62.98	72.66	70.96	77.27	74.05	39.8	42.27	48.14
Coefficient Of Variation	2608.13	885.68	541.45	957.58	440.72	710.7	1315.76	15999.51	(6,428)
Mean Deviation	5.01	2.9	1.56	1.3	1.17	2.34	2.27	2.95	0.7113
Jensen Alpha	(0.34)	0.1336	0.2467	(0.03)	0.2647	0.2671	0.3281	0.0387	(0.06)
Total Risk Alpha	(0.93)	(0.21)	0.0313	(0.13)	0.08	(0.09)	(0.31)	(0.67)	(0.19)
Sortino Ratio	0.02	0.088	0.1736	0.0337	0.1509	0.1001	0.0414	(0.02)	N/A
Downside Variance	46.13	10.62	2.83	3.16	1.81	9.67	7.37	25.83	N/A
Standard Deviation	7.13	3.76	2.33	1.89	1.5	3.19	3.29	4.11	0.9843
Kurtosis	3.49	0.72	10.74	6.77	0.9077	1.07	6.17	1.04	0.919
Potential Upside	10.55	7.69	3.65	3.01	2.92	6.99	5.56	4.17	1.33
Treynor Ratio	0.0561	0.1883	0.3094	0.1119	0.6405	0.3259	(0.35)	(0.09)	(0.10)
Maximum Drawdown	43.96	18.54	15.83	12.15	7.2	13.9	21.17	20.74	4.66
Variance	50.8	14.14	5.42	3.57	2.25	10.18	10.81	16.87	0.9688
Market Risk Adjusted Performance	0.0661	0.1983	0.3194	0.1219	0.6505	0.3359	(0.34)	(0.08)	(0.09)
Risk Adjusted Performance	0.0382	0.0943	0.1479	0.0858	0.1784	0.1152	0.0658	0.0129	(0.01)
Skewness	0.7246	0.5306	2.26	1.57	0.7127	0.2013	1.64	0.2065	(0.84)
Semi Deviation	6.45	2.94	1.26	1.24	0.8393	2.62	2.31	3.38	N/A
Information Ratio	0.019	0.0763	0.1256	0.0316	0.1352	0.0976	0.0342	(0.03)	(0.16)
Value At Risk	(10.60)	(4.73)	(2.16)	(2.50)	(1.94)	(4.19)	(4.50)	(4.00)	(2.38)
Expected Short fall	(5.13)	(3.61)	(2.15)	(1.92)	(1.68)	(2.86)	(2.93)	(4.90)	N/A
Downside Deviation	6.79	3.26	1.68	1.78	1.34	3.11	2.72	5.08	N/A
Semi Variance	41.65	8.67	1.58	1.54	0.7044	6.86	5.32	11.45	N/A

EMERGENT BIOSOLUT Competition Performance Charts

Five steps to successful analysis of EMERGENT BIOSOLUT Competition

EMERGENT BIOSOLUT's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by EMERGENT BIOSOLUT in relation to its competition. EMERGENT BIOSOLUT's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of EMERGENT BIOSOLUT in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact EMERGENT BIOSOLUT's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to EMERGENT BIOSOLUT, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your EMERGENT BIOSOLUT position

In addition to having EMERGENT BIOSOLUT in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Buywrite ETFs Thematic Idea Now

Buywrite ETFs

ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Buywrite ETFs theme has 25 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Buywrite ETFs Theme or any other thematic opportunities.

View All Next

Launch

Other Information on Investing in EMERGENT Stock

EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

EMERGENT Competitors

Specify up to 10 symbols:

EMERGENT BIOSOLUT Competition Correlation Matrix

Risk-Adjusted Indicators

EMERGENT BIOSOLUT Competitive Analysis

EMERGENT BIOSOLUT Competition Performance Charts

Five steps to successful analysis of EMERGENT BIOSOLUT Competition

Complement your EMERGENT BIOSOLUT position

Did You Try This Idea?

Run Buywrite ETFs Thematic Idea Now

Buywrite ETFs

Other Information on Investing in EMERGENT Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY